Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

Libster, 2020
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%
PLACID, 2020
RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
235/229 suggested 4%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).